Searched for
PHARMA MANUFACTURING
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
India has wide AI talent gaps in deployment, governance, security: Quess reportIndia faces significant AI talent gaps in deployment, governance, and security roles, with GenAI deployment showing the widest deficit. Whi...
How India can win in a rewired global economyIndia is poised to gain from global supply chain shifts. Strategic neutrality and domestic focus are key. The nation must build robust buff...
Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
NBFCs and private banks better positioned than PSU banks: Aman ChowhanAman Chowhan of Abakkus Asset Manager highlights crude oil as the dominant macro risk, potentially impacting corporate earnings by 100-200 ...
Falling crude, stronger rupee could boost earnings outlook for India: Deepak ShenoyIndian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...
Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
India's productivity gap with China widens despite strong GDP growth; manufacturing leap still missing: ReportIndia's labour productivity gap with China has widened significantly since 2000, despite strong economic growth. The country has yet to ach...
Call to extend duty cuts on critical inputs soonIndia is set to decide on extending customs duty relief for critical raw material imports beyond June 30. An inter-ministerial panel will r...
Regulators tighten GMP oversight of pharma plantsSeveral states have constituted dedicated multi-member teams to ensure no facility slips through the cracks before a GMP Certificate is iss...
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
Piyush Goyal meets Ernst & Young CEO, discusses India's role in global supply chainsUnion Minister Piyush Goyal said he held a meeting with Janet Truncale, Global Chair and CEO of EY, to discuss India's growing role in glob...
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...
Over 60% of pharma MSMEs yet to comply with updated manufacturing normsPharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...